Meeting
2020 ASCO Virtual Scientific Program
A phase II study of anti-PD1 monoclonal antibody (Nivolumab) administered in combination with anti-LAG3 monoclonal antibody (Relatlimab) in patients with metastatic melanoma naive to prior immunotherapy in the metastatic setting.
Authors
Anjali Rohatgi
UPMC Hillman Cancer Center, Pittsburgh, PA
Anjali Rohatgi , Ryan Campbell Massa , William E. Gooding , Tullia C. Bruno , Dario Vignali , John M. Kirkwood
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03743766
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS10085)
DOI
10.1200/JCO.2020.38.15_suppl.TPS10085
Abstract #
TPS10085
Poster Bd #
434
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
NCT04552223: A phase II study of nivolumab plus BMS-986016 (relatlimab) in patients with metastatic uveal melanoma (UM) (CA224-094).
First Author: Jose Lutzky
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Multicenter phase II study of neoadjuvant nivolumab or nivolumab plus relatlimab (anti-LAG3 antibody) plus chemoradiotherapy in stage II/III esophageal/gastroesophageal junction (E/GEJ) carcinoma.
First Author: Ronan Joseph Kelly
Poster
2020 ASCO Virtual Scientific Program
Design and rationale of MASTERKEY-115 phase II trial of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in patients with advanced melanoma who progressed on prior anti-programmed cell death-1 (anti-PD-1) therapy.
First Author: Jason Alan Chesney
Poster
2020 Gastrointestinal Cancers Symposium
Phase II study of nivolumab and relatlimab in advanced mismatch repair deficient (dMMR) cancers resistant to prior PD-(L)1 inhibition.
First Author: Katherine M. Bever